Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus, according to the American Diabetes Association diagnostic criteria, ≥ 3 months at time of randomization * HbA1c in the range of 6.5 - 9.5% (inclusive) at screening * Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 4 weeks prior to randomization * Further criteria as defined in the clinical trial protocol Exclusion Criteria: * Symptoms of hyperglycemia (i.e. polyuria and polydypsia) * History of significant weight gain or loss (+/-5%) during the 4 weeks before randomization * Fasting C-peptide level \< 400 pmol/L at screening * Change in the medicamentous treatment of elevated blood pressure, diabetes mellitus or dyslipidemia within 4 weeks prior to the randomization * Use of any weight loss medication (over the counter prescription) or initiation of a prescribed weight management or exercise program within 4 weeks before randomization * Current systemic anti-inflammatory therapy other than aspirin ≤ 100 mg/day or immunosuppressive treatment, in particular oral corticosteroids